Sign In
Buy ARKG
$33.15
-0.260 (-0.778%)
At Close: Jun 08, 2026
ARKG: More Than Just Genomes
11:26am, Tuesday, 06'th Jul 2021
COVID-19 has only revealed a small glimpse of the possibilities offered by genomics, a field which is leading us towards predictive and personalized health care. However, ARKG goes beyond just genomic
Genomics ETFs Surge on a Major Breakthrough in CRISPR Study
02:04pm, Wednesday, 30'th Jun 2021
The genomic-editing space has come under the spotlight with the release of encouraging data from a study assessing an in vivo CRISPR-based gene editing therapy candidate, NTLA-2001.
This Explosive Biotech Is Taking On a Huge New Market
11:17am, Wednesday, 30'th Jun 2021
Dominant in its core reproductive health market, niche medical diagnostics company Natera now has its sights on the crowded oncology diagnostics space.
New Gene Editing Trial Results Bump the ARKG ETF
11:39am, Tuesday, 29'th Jun 2021
Shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) surged Monday after the firm and another company known as Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) over the weekend announced positive results
ARK ETFs Grind Higher Amid Chop
04:35pm, Wednesday, 23'rd Jun 2021
The Fed's change in outlook might point to stormier waters ahead for the rebounding ARK suite and other tech-heavy funds.
Cathie Wood Bought This Stock for a Bargain. Should You Follow?
06:00am, Thursday, 17'th Jun 2021
The company is one of Wood's biggest biotech holdings.
Biogen Alzheimer's Approval Could Signal FDA's Flexibility
01:37pm, Tuesday, 15'th Jun 2021
Last week, the Food & Drug Administration (FDA) approved Biogen's Aducanumab, a potentially revolutionary Alzheimer's treatment. While the approval represents one of the first landmarks in the quest t
Top-Performing Biotech ETFs of Last Week
12:02pm, Monday, 14'th Jun 2021
Investors may want to tap the bullishness in the sector with the best biotech ETFs of last week.
ARK: Cathie Wood And The Exquisite Art Of Tail Gunning
10:47am, Monday, 14'th Jun 2021
ARK Active ETFs are worth the management fee. Structured Lookback is introduced.
Nicholas Ward's Dividend Growth Portfolio: May 2021 Review
02:44pm, Thursday, 10'th Jun 2021
During May, I made 13 purchases and 0 sales.
ETF Battles: ARKG Vs GNOM
02:12pm, Monday, 07'th Jun 2021
Which biotech/genomics ETF is the better play?
Pandemic Opening the Door for Widespread Genetic Testing
12:33pm, Wednesday, 02'nd Jun 2021
The COVID-19 pandemic accelerated adoption of an array of disruptive growth technologies, including e-commerce, fintech, and more. Healthcare innovation is part of that trend, and the ARK Genomic Revo
Ride the Renewed Meme Stock Wave With This New ETF
12:02pm, Wednesday, 02'nd Jun 2021
Meme stocks are those that grabbed immense investor interest due to hype on social media and online forums like Reddit, WallStreetBets and Robinhood, rather than the company fundamentals, resulting in
With Expenses Growing Faster Than Revenue, Is This Cathie Wood Stock in Trouble?
06:11am, Saturday, 22'nd May 2021
Guardant Health released earnings earlier this month, disappointing investors with its sluggish revenue growth and increasing expenses.
High Flying ETFs Reverse Course
02:13pm, Wednesday, 19'th May 2021
From 'ARKK' to 'SPAK' to 'IPO,' these once-hot ETFs have noticeably cooled.
